GOSSAMER BIO, INC.

GOSS ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Balance Sheet
Annual Quarterly

Balance Sheet

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Assets
Cash & Equivalents $37.7M $46.1M $32.1M $112.0M $183.4M $486.1M $135.0M $105.2M
Accounts Receivable $12.2M $5.3M $0
Inventory
Total Current Assets $167.6M $309.9M $306.5M $261.9M $331.8M $522.3M $409.3M $232.0M
Property, Plant & Equipment $64.0K $10.0K $1.6M $4.0M $5.3M $5.5M $5.4M $3.2M
Goodwill
Intangible Assets (Excl. Goodwill)
Total Assets $172.2M $315.3M $311.9M $272.5M $343.7M $539.4M $426.6M $239.4M
Liabilities
Accounts Payable $6.0M $2.3M $5.5M $1.5M $3.2M $7.5M $956.0K $2.2M
Total Current Liabilities $63.4M $45.0M $51.6M $49.2M $39.9M $38.7M $36.9M $20.4M
Long-Term Debt $0 $814.0K $12.0M $29.1M $28.7M $28.5M
Total Liabilities $295.0M $285.8M $249.1M $260.4M $222.2M $218.7M $74.1M $21.1M
Stockholders' Equity
Retained Earnings $-1.44B $-1.27B $-1.21B $-1.03B $-811.5M $-577.5M $-334.2M $-153.9M
Total Stockholders' Equity $-122.8M $29.5M $62.8M $12.1M $121.5M $320.7M $352.5M $-120.1M
← Newer Page 1 of 2 Older →